Suppr超能文献

小脑变性相关蛋白2和2样蛋白在有或没有Yo抗体的卵巢癌患者中均有存在。

Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.

作者信息

Raspotnig Margrethe, Haugen Mette, Thorsteinsdottir Maria, Stefansson Ingunn, Salvesen Helga B, Storstein Anette, Vedeler Christian A

机构信息

Department of Clinical Medicine, University of Bergen, Jonas Lies veg 87, 5021, Bergen, Norway.

Department of Neurology, Haukeland University Hospital, Jonas Lies veg 65, 5021, Bergen, Norway.

出版信息

Cancer Immunol Immunother. 2017 Nov;66(11):1463-1471. doi: 10.1007/s00262-017-2041-8. Epub 2017 Jul 14.

Abstract

BACKGROUND

Cerebellar degeneration-related protein 2 (CDR2) has been presumed to be the main antigen for the onconeural antibody Yo, which is strongly associated with ovarian cancer and paraneoplastic cerebellar degeneration (PCD). Recent data show that Yo antibodies also target the CDR2-like protein (CDR2L). We, therefore, examined the expression of CDR2 and CDR2L in ovarian cancer tissue from patients with and without Yo antibodies and from various other cancerous and normal human tissues.

METHODS

Ovarian cancer tissue and serum samples from 16 patients were included in the study (four with anti-Yo and PCD, two with anti-Yo without PCD, five with only CDR2L antibodies, and five without onconeural antibodies). Clinical data were available for all patients. The human tissues were examined by western blot and immunohistochemistry using rabbit CDR2 and CDR2L antibodies.

RESULTS

Ovarian cancers from all 16 patients expressed CDR2 and CDR2L proteins. Both proteins were also present in normal and cancer tissue from mammary tissue, kidney, ovary, prostate, and testis.

CONCLUSION

CDR2L is present in ovarian cancers from patients with and without Yo antibodies as was shown previously for CDR2. In addition, both CDR2 and CDR2L proteins are more widely expressed than previously thought, both in normal and cancerous tissues.

摘要

背景

小脑变性相关蛋白2(CDR2)被认为是肿瘤神经抗体Yo的主要抗原,该抗体与卵巢癌和副肿瘤性小脑变性(PCD)密切相关。最近的数据显示,Yo抗体也靶向CDR2样蛋白(CDR2L)。因此,我们检测了有或没有Yo抗体的卵巢癌患者的癌组织以及其他各种癌组织和正常人体组织中CDR2和CDR2L的表达。

方法

本研究纳入了16例患者的卵巢癌组织和血清样本(4例有抗Yo抗体且患有PCD,2例有抗Yo抗体但无PCD,5例仅有CDR2L抗体,5例无肿瘤神经抗体)。所有患者均有临床资料。使用兔CDR2和CDR2L抗体通过蛋白质印迹法和免疫组织化学法检测人体组织。

结果

16例患者的所有卵巢癌均表达CDR2和CDR2L蛋白。这两种蛋白也存在于乳腺组织、肾脏、卵巢、前列腺和睾丸的正常组织和癌组织中。

结论

如先前对CDR2的研究所示,CDR2L存在于有或没有Yo抗体的卵巢癌患者中。此外,CDR2和CDR2L蛋白在正常组织和癌组织中的表达比先前认为的更广泛。

相似文献

1
Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.
Cancer Immunol Immunother. 2017 Nov;66(11):1463-1471. doi: 10.1007/s00262-017-2041-8. Epub 2017 Jul 14.
2
CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.
PLoS One. 2013 Jun 18;8(6):e66002. doi: 10.1371/journal.pone.0066002. Print 2013.
3
CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration.
Ann Neurol. 2019 Aug;86(2):316-321. doi: 10.1002/ana.25511. Epub 2019 Jun 13.
5
Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.
Ann Clin Transl Neurol. 2020 Nov;7(11):2231-2242. doi: 10.1002/acn3.51212. Epub 2020 Oct 3.
6
CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity.
Front Immunol. 2023 Sep 29;14:1265797. doi: 10.3389/fimmu.2023.1265797. eCollection 2023.
7
Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.
Neurol Neuroimmunol Neuroinflamm. 2021 Feb 2;8(2). doi: 10.1212/NXI.0000000000000963. Print 2021 Mar.
8
Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.
Acta Neuropathol. 2014 Dec;128(6):835-52. doi: 10.1007/s00401-014-1351-6. Epub 2014 Oct 24.
9
CDR2 antigen and Yo antibodies.
Cancer Immunol Immunother. 2011 Feb;60(2):283-9. doi: 10.1007/s00262-010-0943-9. Epub 2010 Nov 16.
10
Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.
Acta Neuropathol. 2018 Apr;135(4):569-579. doi: 10.1007/s00401-017-1802-y. Epub 2018 Jan 3.

引用本文的文献

1
Case Report: Anti-Yo antibody mediated paraneoplastic cerebellar degeneration in a patient with squamous cell lung carcinoma.
Front Immunol. 2025 Mar 21;16:1558867. doi: 10.3389/fimmu.2025.1558867. eCollection 2025.
2
3
Case report: paraneoplastic cerebellar degeneration associated with anti-Yo antibody successfully treated with ofatumumab.
Front Immunol. 2024 Dec 16;15:1476397. doi: 10.3389/fimmu.2024.1476397. eCollection 2024.
4
Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology.
Ann Neurol. 2024 Nov;96(5):1020-1025. doi: 10.1002/ana.27033. Epub 2024 Jul 15.
5
Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors.
Biomedicines. 2024 Jun 13;12(6):1319. doi: 10.3390/biomedicines12061319.
6
Prediction of CAF-related genes in immunotherapy and drug sensitivity in hepatocellular carcinoma: a multi-database analysis.
Genes Immun. 2024 Feb;25(1):55-65. doi: 10.1038/s41435-024-00252-z. Epub 2024 Jan 17.
9
An Etiological Investigation of Paraneoplastic Cerebellar Degeneration in Ovarian Cancer Patients: A Systematic Review.
Cureus. 2022 Nov 6;14(11):e31154. doi: 10.7759/cureus.31154. eCollection 2022 Nov.
10
A Breakdown of Immune Tolerance in the Cerebellum.
Brain Sci. 2022 Feb 28;12(3):328. doi: 10.3390/brainsci12030328.

本文引用的文献

1
Expression of Yo Antigen in a Prostatic Adenocarcinoma.
Can J Neurol Sci. 2017 Mar;44(2):221-223. doi: 10.1017/cjn.2016.400.
2
CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model.
Brain. 2016 Nov 1;139(11):2923-2934. doi: 10.1093/brain/aww225.
3
Proteolytic degradation and potential role of onconeural protein cdr2 in neurodegeneration.
Cell Death Dis. 2016 Jun 2;7(6):e2240. doi: 10.1038/cddis.2016.151.
4
Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.
J Neurol. 2016 May;263(5):1001-1007. doi: 10.1007/s00415-016-8090-7. Epub 2016 Mar 23.
5
Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.
Acta Neuropathol. 2014 Dec;128(6):835-52. doi: 10.1007/s00401-014-1351-6. Epub 2014 Oct 24.
7
Staging classification for cancer of the ovary, fallopian tube, and peritoneum.
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5. doi: 10.1016/j.ijgo.2013.10.001. Epub 2013 Oct 22.
8
CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.
PLoS One. 2013 Jun 18;8(6):e66002. doi: 10.1371/journal.pone.0066002. Print 2013.
9
New insights into ovarian cancer pathology.
Ann Oncol. 2012 Sep;23 Suppl 10:x111-7. doi: 10.1093/annonc/mds300.
10
Onconeural antibodies: improved detection and clinical correlations.
J Neuroimmunol. 2011 Mar;232(1-2):166-70. doi: 10.1016/j.jneuroim.2010.10.009. Epub 2010 Nov 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验